Overview: Leukemia Plasma Cell Dyscrasias Panel
Introduction: The Leukemia Plasma Cell Dyscrasias Panel is a diagnostic tool designed to diagnose plasma cell dyscrasias using whole blood or bone marrow samples. In India, multiple myeloma and related disorders (MGUS, smoldering MM, plasmacytoma) affect ~10,000â€"15,000 new cases/year, with plasma cell markers (CD38, CD138, kappa/lambda restriction) essential for confirmation. High morbidity from under-testing in rural/low-SES patients with bone pain, anemia, renal failure, limited flow labs, delayed bortezomib/lenalidomide leading to skeletal complications or ESRD. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 34 plasma cell markers (CD38, CD138, CD19, CD56, CD45, cytoplasmic kappa/lambda, etc.) over 1-2 days with high accuracy, valuable for clonality assessment and risk stratification. This diagnostic falls under leukemia screening and targets patients with monoclonal protein, lytic lesions, or renal impairment, addressing accurate detection to guide induction therapy or ASCT. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise plasma cell profiling and improving myeloma survival. Its blood/bone marrow-based approach ensures reliable marker analysis.
Other Names: Plasma Cell Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.
Historical Milestone: Plasma cell flow standard; in India, routine in myeloma centers.
Purpose: The test assesses 34 parameters including plasma cell markers to guide diagnosis of dyscrasias, detect clonality, inform therapy.
Test Parameters: 1â€"34. Plasma Cell Markers (CD38, CD138, Kappa, Lambda, etc.).
Pretest Condition: No fasting required; patients should have monoclonal protein or bone pain.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow/PCR).
Medical History: Patients should provide details on anemia, renal function, lytic lesions.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed myeloma including renal failure, benefits of profiling, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low plasma cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: CD38+/CD138+ with light chain restriction confirms plasma cell dyscrasia, necessitating specialist input.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: Serum FLC, bone marrow biopsy for confirmation.
Test Limitations: Requires viable plasma cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Myeloma Studies India 2023.
